25 January 2024
25 January 2024
Amid increased restrictions on contraceptive care, HHS released plans pushing for full access to all FDA-approved contraceptives.
Despite the setback, the current commercial availability of the F4 formulation of tesamorelin remains unaffected.
Pfizer will charge $1,400 per five-day course of Paxlovid as the drug moves over to commercial sales.
The company plans to commence a Phase II global clinical trial of NS-229 shortly.
Kyowa Kirin has gained access to Orchard’s portfolio including Libmeldy, a gene therapy approved for metachromatic leukodystrophy (MLD).
Excluding the impact of its Covid-19 vaccine, operational growth was an impressive 10.9%.
The funding will primarily support the development of the company’s lead programmes, SNV1521 and SNV4818.
The vaccines will target endogenous retroviruses (ERVs) – ancient virus remnants dormant in human genomes that are often overexpressed in cancer cells.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
